Goubergrits L., Wellnhofer E., Kertzscher U. "Saliva is comparable to nasopharyngeal swabs for molecular detection of SARS-CoV-2". Callahan C., Ditelberg S., Dutta S., et al. "COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia?" Lancet 2020 395:1758-1759. Maier C.L., Truong A.D., Auld S.C., Polly D.M., Tanksley C.-L., Duncan A. "Therapeutic plasma exchange for COVID-19-associated hyperviscosity". Truong A.D., Auld S.C., Barker N.A., et al. "Blood hyperviscosity in acute and recent COVID-19 infection". "Plasma and blood viscosity in the prediction of cardiovascular disease and mortality in the Scottish Heart Health Extended Cohort Study". Peters S.A., Woodward M., Rumley A., Tunstall-Pedoe H.D., Lowe G.D. "Cardiovascular risks of anemia correction with erythrocyte stimulating agents: should blood viscosity be monitored for risk assessment?" Cardiovasc Drugs Ther 2010 24:151-160. Jeong S.-K., Cho Y.I., Duey M., Rosenson R.S. "Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19". Bonaventura A., Vecchié A., Dagna L., et al. "IL-6–based mortality risk model for hospitalized patients with COVID-19". Laguna-Goya R., Utrero-Rico A., Talayero P., et al. "Troponin and other biomarker levels and outcomes among patients hospitalized with COVID-19: derivation and validation of the HA 2 T 2 COVID-19 Mortality Risk Score". Manocha K.K., Kirzner J., Ying X., et al. "Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis". Henry B.M., de Oliveira M.H.S., Benoit S., Plebani M., Lippi G.
"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19". Ackermann M., Verleden S.E., Kuehnel M., et al. "Autopsy findings and venous thromboembolism in patients with COVID-19". Wichmann D., Sperhake J.-P., Lütgehetmann M., et al.
0 kommentar(er)
